Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Operating Leases: 2019-2024

Historic Operating Leases for Rocket Pharmaceuticals (RCKT) over the last 6 years, with Dec 2024 value amounting to $3.3 million.

  • Rocket Pharmaceuticals' Operating Leases fell 19.19% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 19.19%. This contributed to the annual value of $3.3 million for FY2024, which is 9.59% up from last year.
  • Rocket Pharmaceuticals' Operating Leases amounted to $3.3 million in FY2024, which was up 9.59% from $3.0 million recorded in FY2023.
  • In the past 5 years, Rocket Pharmaceuticals' Operating Leases ranged from a high of $3.3 million in FY2024 and a low of $498,000 during FY2020.
  • Moreover, its 3-year median value for Operating Leases was $3.0 million (2023), whereas its average is $2.4 million.
  • Its Operating Leases has fluctuated over the past 5 years, first slumped by 65.49% in 2020, then spiked by 173.25% in 2023.
  • Yearly analysis of 5 years shows Rocket Pharmaceuticals' Operating Leases stood at $498,000 in 2020, then skyrocketed by 81.73% to $905,000 in 2021, then climbed by 20.22% to $1.1 million in 2022, then skyrocketed by 173.25% to $3.0 million in 2023, then increased by 9.59% to $3.3 million in 2024.